- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BMS-790052 | BMS790052 | Daklinza®
daclatasvir is an approved drug (EMA (2014), FDA (2015))
Compound class: Synthetic organic
Comment: Daclatasvir is an orally available anti-hepatitis C virus (HCV) drug, It is a direct-acting inhibitor of the non-structural protein 5A (NS5A) replication complex of HCV . Blocking NS5A function inhibits viral RNA replication and virion assembly.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Compound class||Synthetic organic|
|Approved drug?||Yes (EMA (2014), FDA (2015))|
|WHO Essential Medicine||WHO Essential Medicines List (EML) (22nd List, 2021). Access PDF version.
Click to view more information about the WHO Model Lists of Essential Medicines.
|International Nonproprietary Names|
|BMS-790052 | BMS790052 | Daklinza®|
|CAS Registry No.||1009119-64-5 (source: PubChem)|
|GtoPdb PubChem SID||434321701|
|Search Google for chemical match using the InChIKey||FKRSSPOQAMALKA-CUPIEXAXSA-N|
|Search Google for chemicals with the same backbone||FKRSSPOQAMALKA|
|Search PubMed clinical trials||daclatasvir|
|Search PubMed titles||daclatasvir|
|Search PubMed titles/abstracts||daclatasvir|
|Search UniChem for chemical match using the InChIKey||FKRSSPOQAMALKA-CUPIEXAXSA-N|
|Search UniChem for chemicals with the same backbone||FKRSSPOQAMALKA|